Global Prothrombin Complex Concentrate(PCC) Market Growth 2023-2029

Global Prothrombin Complex Concentrate(PCC) Market Growth 2023-2029

Mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiencies (alone or in combination) including: coagulation factor IX deficiency (hemophilia B), and coagulation factor II, VII, X deficiency overdose of anticoagulants, vitamin K deficiency; patients with hemorrhage caused by liver disease need to correct coagulation dysfunction; when disseminated intravascular coagulation (DIC) occurs, coagulation factors II, VII, IX, and X are consumed in large quantities, which can be used in heparin Application after chemotherapeutic; prothrombin time prolongation due to various reasons and intended for surgery, but may be ineffective for those with coagulation factor V deficiency; treatment of bleeding symptoms in patients with hemophilia A who have produced factor VIII preparations ; Reversal of coumarin anticoagulant-induced bleeding.

LPI (LP Information)' newest research report, the “Prothrombin Complex Concentrate(PCC) Industry Forecast” looks at past sales and reviews total world Prothrombin Complex Concentrate(PCC) sales in 2022, providing a comprehensive analysis by region and market sector of projected Prothrombin Complex Concentrate(PCC) sales for 2023 through 2029. With Prothrombin Complex Concentrate(PCC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prothrombin Complex Concentrate(PCC) industry.

This Insight Report provides a comprehensive analysis of the global Prothrombin Complex Concentrate(PCC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prothrombin Complex Concentrate(PCC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Prothrombin Complex Concentrate(PCC) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prothrombin Complex Concentrate(PCC) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prothrombin Complex Concentrate(PCC).

The global Prothrombin Complex Concentrate(PCC) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Prothrombin Complex Concentrate(PCC) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Prothrombin Complex Concentrate(PCC) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Prothrombin Complex Concentrate(PCC) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Prothrombin Complex Concentrate(PCC) players cover CSL, Beijing Tiantan Biological Products, SHANGHAI RAAS, Biotest, Taibang Biologic Group, HUALAN BIOLOGICAL ENGINEERING, WEIGUANG BIOLOGICAL, Green Cross and BOHUI, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Prothrombin Complex Concentrate(PCC) market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
100IU
200IU
300IU
400IU
1000IU

Segmentation by application
Hopistial
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CSL
Beijing Tiantan Biological Products
SHANGHAI RAAS
Biotest
Taibang Biologic Group
HUALAN BIOLOGICAL ENGINEERING
WEIGUANG BIOLOGICAL
Green Cross
BOHUI
Guangdong Shuanglin Biopharmaceutical
Jiangxi Boya Bio-Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Prothrombin Complex Concentrate(PCC) market?

What factors are driving Prothrombin Complex Concentrate(PCC) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Prothrombin Complex Concentrate(PCC) market opportunities vary by end market size?

How does Prothrombin Complex Concentrate(PCC) break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.